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T he optimal therapy for women with breast cancer is determined based on the cancer subtype,  with 
different subtypes responding better to adjuvant endo-
crine therapy,  chemotherapy,  or anti-HER2 agents 
[1-3].  In metastatic scenarios,  treatment is similarly 
determined based on subtypes.  Owing to new drugs,  
such as aromatase inhibitors and trastuzumab,  the 
prognoses for patients with recurrent breast cancer have 
improved over time for hormone-receptor-positive and/
or human epidermal growth factor receptor type 2-pos-
itive breast cancer [4 , 5].  Moreover,  new agents such 
pertuzumab,  trasutuzumab emtansine,  fulvestrant,  
mammalian target of rapamycin inhibitors,  and 
cyclin-dependent kinase 4/6 inhibitors can be used,  and 
will continue to provide patients with further treatment 
options.
Although new drugs which can lead to improved 
prognoses for cancer patients have been developed,  
these drugs can be extremely expensive.  Indeed,  cancer 
treatments can be “financially toxic,” as high out-of-
pocket medical costs are associated with lower quality of 
Acta Med.  Okayama,  2020
Vol.  74,  No.  2,  pp.  95-101
CopyrightⒸ 2020 by Okayama University Medical School.
http ://escholarship.lib.okayama-u.ac.jp/amo/Original Article
The Efficacy of Software to Help Patients Understand Drug for Adjuvant 
Treatment for Breast Cancer: A Pilot Randomized Controlled Trial
Sayaka Kubaa＊,  Kosho Yamanouchia,  Michi Moritaa,  Chika Sakimuraa,   
Eiko Inamasub,  Toshiko Hatachib,  Ryota Otsubob,  Megumi Matsumotob,   
Hiroshi Yanob,  Junya Miyamotoc,  Shuntaro Satoc,  Hiroo Nakagawad,   
Kengo Kanetakaa,  Mitsuhisa Takatsukia,  Takeshi Nagayasub,  and Susumu Eguchia
Departments of  aSurgery,  bSurgical Oncology,  dPharmacy,  cClinical Research Center,   
Nagasaki University Graduate School of Biomedical Science,  Nagasaki 852-8501,  Japan
We assessed the usefulness of ChemoCalc,  a software package for calculating drug costs,  in helping patients 
understand these costs.  We randomly assigned,  in a 1 : 1 ratio,  20 women who had undergone surgery for early 
breast cancer to a group that discussed adjuvant treatment with their physicians using the ChemoCalc software 
(ChemoCalc group) or a group that discussed adjuvant treatment without ChemoCalc (Usual Explanation 
group).  The participants completed a five-grade evaluation questionnaire after these discussions.  The primary 
endpoint was the intergroup comparison of the questionnaire scores regarding participants’ understanding of 
their treatment-associated drug costs.  Median age was not significantly different between the ChemoCalc group 
and Usual Explanation group (57 vs. 50,  respectively; p= 0.27).  Patients in the ChemoCalc group had a signifi-
cantly higher perceived level of understanding of the drug cost than those in the Usual Explanation group 
(5 [4-5] vs. 2.5 [1-5],  respectively; p= 0.002).  Scores related to the patients’ perception that understanding drug 
costs is an important part of breast cancer treatment were also higher in the ChemoCalc group than the Usual 
Explanation group (5 [2-5] vs. 3 [1-5],  respectively; p= 0.049).  ChemoCalc was found to be useful for under-
standing drug costs.
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life and/or delayed or forgone care,  and lead to an 
increased risk of adverse health outcomes [6 , 7].
Shared decision-making is a process in which the 
clinician and patient jointly participate in a health deci-
sion after discussing the options and potential benefits 
and disadvantages,  while considering the patient’s val-
ues [8].  This discussion also includes financial issues 
related to treatment.  Although the importance of com-
municating costs has been reported,  rarely do discus-
sions on this topic actually take place [9].  Barriers to 
cost-related discussions include uncertainty about 
prices,  uncertainty about cost-sharing arrangements,  
and insufficient training of medical personnel.
In this context,  an investigation into the efficacy of 
ChemoCalc (Nippon Chemiphar,  Tokyo; https://www.
nc-medical.com/chemiphar_oncology/chemocalc.
html)—freely downloadable software for calculating 
drug costs—in helping patients and their physicians to 
understand treatment-associated drug costs would be of 
benefit.  To date,  no such analysis has been reported.  
We conducted this pilot study to explore the software’s 
effectiveness for female breast cancer patients.
Patients and Methods
Patients. This study was approved by the 
Nagasaki University Hospital Clinical Research Ethical 
Committee (registration number 17112001),  and all 
patients provided informed consent.  Eligible patients 
were women with early breast cancer,  20 years of age or 
older,  who had undergone surgery for their cancer,  and 
who had yet to discuss adjuvant therapy.  Patients who 
had undergone neoadjuvant treatment were excluded.
ChemoCalc use (Fig. 1). The patient’s share of 
medical expenses is determined by his or her age and 
income in Japan.  A co-payment of 10%,  20%,  or 30% 
of the medical costs is required,  though maximum lev-
els exist.  For patients undergoing cancer treatment,  a 
physician enters the patient’s height and weight into the 
ChemoCalc software,  which then calculates the body 
surface area (Fig. 1A).  The regimen is then selected 
(Fig. 1B shows the selection of an epirubicin regimen),  
and the full cost of the anticancer drugs and antiemet-
ics—as well as 10%,  20%,  and 30% of those costs—is 
given.  ChemoCalc also calculates the costs of endocrine 
therapy,  molecular target therapy,  antiemetic drugs,  
and granulocyte colony-stimulating factor.
Study design. This was a prospective,  single- 
center,  pilot randomized controlled study.  Twenty 
patients were recruited at Nagasaki University to partic-
ipate in the study from December 2017 to August 2018.  
After the physician received the patients’ consent,  the 
patients completed a questionnaire including the State-
Trait Anxiety Inventory (STAI) [10].  The STAI is a 
commonly used measure of trait and state anxiety.  It 
has 20 items for assessing trait anxiety and 20 for 
assessing state anxiety.  All items are rated on a 4-point 
scale.  Higher scores indicate greater anxiety.
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Fig. 1　 ChemoCalc (original Japanese translated to English).  Can be downloaded or used on the web for free.  I obtained reprint per-
mission.  A,  Title page of ChemoCalc; B,  Drug cost for a patient who is 155 cm in height and 48 kg in weight,  using an epirubicin regime.
Based on the scores,  we categorized patients as hav-
ing higher anxiety (45-80) or lower anxiety (20-44).  
Eligible patients were randomly assigned to discuss 
adjuvant treatment with their physicians using the 
ChemoCalc software (ChemoCalc group) or to discuss 
adjuvant treatment without ChemoCalc (Usual 
Explanation group) in the discussion.  Patients within 
each group were stratified by their STAI scores In the 
ChemoCalc group,  the physician took part in shared 
decision-making regarding adjuvant therapy using 
pathological data,  prognosis data (PREDICT v2.1 tool),  
and ChemoCalc.  In the Usual Explanation group,  the 
physician took part in such decision-making using only 
the pathological data and prognosis data (PREDICT 
v2.1 tool).  The same physician conducted all such dis-
cussions.  The physician usually did not explain the drug 
cost,  and so the Usual Explanation group did not 
receive the drug cost without using the description pro-
vided by the drug manufacturer.  After the discussion,  
the patients completed a five-grade evaluation ques-
tionnaire (Table 1).  Higher scores indicated a higher 
degree of agreement with the question content.
Study end points. The primary endpoint was the 
comparison of the 2 groups’ questionnaire scores 
regarding the patients’ perceived level of understanding 
of the drug cost (Table 1,  question 2).  The secondary 
end points were other scores from the questionnaires.  
Finally,  because explaining the use of ChemoCalc and 
the drug costs represents a potentially burdensome time 
expenditure for physicians,  we calculated the total dis-
cussion time.
Statistical analysis. Respondents’ clinicopatho-
logical features and questionnaires were compared 
between the ChemoCalc and Usual Explanation groups.  
Variables were provided as frequencies for categorical 
variables and median and interquartile ranges for quan-
titative variables.  Associations between variables were 
assessed using Fisher’s exact test for categorical variables 
and the Mann–Whitney U test for quantitative variables.  
All statistical analyses were performed with EZR soft-
ware (Saitama Medical Center,  Jichi Medical University,  
Saitama,  Japan),  which is a graphical user interface for 
the R (version 2.13.0,  The R Foundation for Statistical 
Computing) environment; more precisely,  it is a mod-
ified version of R Commander (version 1.6-3) including 
statistical functions frequently used in biostatistics [11].  
Values of p < 0.05 were considered statistically signifi-
cant.
Results
Patients. A total of 20 female Japanese breast 
cancer patients,  with ages ranging from 32-71 years,  
were recruited (Fig. 2).  Ten were assigned to the 
ChemoCalc group and 10 to the Usual Explanation 
group (Table 2).  Patient characteristics are shown in 
Table 2.  Although the Usual Explanation group tended 
to be younger and to more of the patients have had che-
motherapy than the ChemoCalc group,  there were no 
statistically significant differences in any factors 
between the groups.
Comparison of questionnaire scores between the 
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Table 1　 Questionnaire Items
 1. Did you feel comfortable about talking with the physician during the discussion?
 2. Do you understand the drug cost?
 3. Do you think the drug cost is important when deciding on adjuvant therapy?
 4. Are you worried about the drug cost?
 5. Do you understand the treatment choice?
 6. Do you understand the drugsʼ efficacy?
 7. Do you understand the drugsʼ potential adverse events?
 8. Do you have positive feelings about undergoing breast cancer treatment?
 9. Are you employed?
10. (Only ChemoCalc group) Was ChemoCalc easy to understand?
ChemoCalc and Usual Explanation groups (Table 3).  
The primary endpoint was defined as comparing the 
questionnaire scores for the patients’ perceived level of 
understanding of the drug cost between the ChemoCalc 
group and the Usual Explanation group; the scores for 
the ChemoCalc group were significantly higher 
(ChemoCalc group vs. Usual Explanation group;  
5 [4-5] vs. 2.5 [1-5],  respectively; p = 0.002).  The scores 
representing the perception of patients that drug costs 
are an important part of breast cancer treatment were 
also higher in the ChemoCalc group (ChemoCalc group 
vs. Usual Explanation group; 5 [2-5] vs. 3 [1-5],  
respectively; p = 0.049).  In contrast,  no significant 
between-group differences were seen in the patients’ 
understanding of drug efficacy,  understanding of 
drug-related adverse events,  or positive feelings toward 
treatment.  Patients in the ChemoCalc group had high 
scores on the item stating that ChemoCalc was easy to 
understand.  The discussion time needed for the expla-
nation of another clinical trial was also not significantly 
different between the groups (ChemoCalc group vs. 
Usual Explanation group; 25 min [13-36] vs. 33 min 
[15-58],  respectively; p = 0.10).
Discussion
This report describes a pilot randomized controlled 
trial that was conducted to examine the efficacy of 
ChemoCalc in women with breast cancer who were 
making a decision regarding adjuvant treatment.  
Patients’ perceived levels of understanding of drug costs 
and the importance of such costs were found to be 
higher in the group whose consultation included 
ChemoCalc.
Another report [12] found that the discussion of 
costs is a crucial component of clinical decision-making 
for a number of reasons.  Discussing out-of-pocket costs 
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Table 2　 Clinical Factors in Usual Explanation Group and ChemoCalc Group
Usual Explanation group ChemoCalc group P-value
Median age (range) 50 (32-71) 57 (48-67) 0.27
State-Trait Anxiety Inventory
High/low 3/7 4/6
1
Breast surgery
Mastectomy/Lumpectomy 4/6 6/4 0.66
Lymph node surgery
Ax/SN 1/9 1/9 1
Subtype
Luminal/Luminal HER2/HER2-enriched/TN 8/1/1/0 9/1/0/0 1
Endocrine therapy
Yes/No 9/1 10/0 1
Chemotherapy
Yes/No 5/5 2/8 0.35
Ax,  Axillary dissection; SN,  Sentinel lymph node biopsy.
STAI (The stratification factor)
High: 7 
Low: 13
Usual explanation group
(n=10)
ChemoCalc group
(n=10)
Patients recruited
(n=20)
Fig. 2　 Flowchart of patients.
enables patients to choose lower-cost treatments when 
viable alternatives are available.  Such discussions may 
also assist patients who are willing to trade off some 
chance of medical benefit in return for less finance- 
related distress.  Additionally,  discussing such costs can 
benefit patients by enabling them to seek financial assis-
tance early enough in their care to minimize financial 
distress.  Furthermore,  a growing body of evidence 
suggests that including a consideration of costs in clini-
cal decision-making may reduce costs for patients and 
society in the long term [12].  In fact,  one report on 
bladder cancer patients showed that patients struggling 
with finances experienced worse physical and mental 
health,  and lower cancer-specific health-related quality 
of life,  physical well-being,  and functional well-being 
[13].  The American Society of Clinical Oncology 
(ASCO) advocated a conceptual framework for assess-
ing the value of cancer treatment options.  Through its 
Value in Cancer Care Task Force,  ASCO defines value 
in cancer care by emphasizing clinical benefit (efficacy),  
toxicity (safety),  and cost (efficiency).  This framework 
enables beneficial conversations between physicians and 
patients about the value of a new therapy over an 
accepted standard [14].
A survey of needs in the cost conversation found 
that 63% of patients and 79% of physicians wanted to 
discuss patients’ out-of-pocket costs,  though only 15% 
of patients and 35% of physicians did so [9].  Another 
report found that breast cancer patients wanted to dis-
cuss the costs of care [15].  This raises the question of 
why patients and physicians often fail to have conversa-
tions about costs when they both report that they want 
to.  Reported barriers to discussing out-of-pocket costs 
with patients include the premise that an ethical physi-
cian should not withhold beneficial treatments because 
of cost,  uncertainty about prices,  uncertainty about 
cost-sharing arrangements,  and insufficient training 
[16 , 17].  In Japan,  patients’ co-payments are deter-
mined based on their age and income—10%,  20%,  or 
30% of the full medical costs—though maximum levels 
exist,  and almost all patients are aware of what their 
co-payments will be.  ChemoCalc calculates 10%,  20%,  
and 30% of the entire drug cost.  In this pilot study,  
ChemoCalc enabled patients to easily understand drug 
costs while not requiring a great deal of their physician’s 
time.  Previous surveys have examined the needs or the 
importance of cost conversations,  but there have been 
no interventional studies on overcoming the cost com-
munication barrier.  The present study shows,  and fur-
ther studies will elaborate,  that the barrier of uncer-
tainty about prices can be overcome.  Physicians should 
seek to overcome barriers in cost communication to 
achieve true shared decision-making.
Among the participants in this study,  more subjects 
in the ChemoCalc group than in the Usual Explanation 
group expressed the opinion that drug cost was an 
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Table 3　 Results of Questionnaire (Table 1)
Usual Explanation group ChemoCalc group P-value
1. Comfortable discussion# 5 (5-5) 5 (4-5) 0.37
2. Understanding of drug cost# 2.5 (1-5) 5 (4-5) 0.002
3. Importance of drug cost# 3 (1-5) 5 (2-5) 0.049
4. Worried about drug cost# 3 (1-5) 3.5 (1-5) 0.79
5. Understanding of treatment choice# 5 (5-5) 5 (5-5) 1
6. Understanding of drug efficacy# 5 (5-5) 5 (5-5) 1
7. Understanding of drugsʼ adverse events# 5 (4-5) 5 (4-5) 0.58
8. Positive feelings about treatment# 5 (3-5) 5 (4-5) 0.58
9. Employed Yes/No 7/3 6/4 1
10. Ease of understanding ChemoCalc 5 (4-5)
Median discussion minutes (range) 33 (15-58) 25 (13-36) 0.10
#These scores were median and range.
important consideration in their treatment.  Because 
patients in the latter group may not have understood 
the costs,  they may not have realized their importance.  
Previous research suggests that high out-of-pocket costs 
are associated with medication nonadherence [18].  We 
have reported that Japanese women with breast cancer 
have high adherence to adjuvant endocrine therapy 
[19 , 20],  and we can add that patients who start adju-
vant therapy without understanding drug costs may be 
more likely to be nonadherent.  Participants in the pres-
ent study for whom adjuvant chemotherapy was recom-
mended had less anxiety about drug costs,  which may 
be related to the anxiety about the side effects of che-
motherapy being a higher priority than cost anxiety.
Our study had some limitations.  First,  because we 
enrolled patients who had undergone surgery for their 
cancer,  but who had yet to discuss adjuvant therapy,  we 
excluded patients who had undergone neoadjuvant che-
motherapy.  At our institution,  we recommend neoad-
juvant treatment for patients with the HER2-positive 
and triple-negative subtypes.  Because of this,  only 
three patients with HER2-positive disease and only 7 
patients who received chemotherapy were enrolled in 
this study.  Chemotherapy and anti-HER2 drugs are 
more expensive than endocrine therapy; therefore,  
future studies should include patients who undergo 
neoadjuvant chemotherapy.  Second,  as we sought to 
investigate the usefulness of ChemoCalc in helping 
patients understand drug costs,  we enrolled only 
patients without metastasis.  Because high-cost drugs 
are mainly used in a metastatic setting,  patients with 
metastatic disease should also be included in future 
studies.  Third,  because this was a pilot study,  we did 
not pursue whether there were differences in treatment 
choices and compliance.  That is a topic to explore in 
future studies.
This study revealed that the use of ChemoCalc soft-
ware greatly improved female breast cancer patients’ 
perception that they could understand the cost of drugs,  
and without a large time commitment for the partici-
pating physician.  We plan to conduct a multicenter 
phase 2 randomized controlled study to further explore 
the usefulness of ChemoCalc and how it affects physi-
cian–patient discussions.
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